PCSK9 monoclonal antibodies: An overview

PCSK9 monoclonal antibodies: An overview

PCSK9 monoclonal antibodies are novel lipid-lowering therapy that have been extensively studied in patients with hypercholesterolemia either as monotherapy or as an add-on to other LLTs. PCSK9 monoclonal antibodies have significantly reduced the low-density lipoprotein cholesterol (LDL-C) plasma lev...

Full description

Bibliographic Details
Main Authors:	Rasha Kaddoura, Bassant Orabi, Amar M Salam
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2020-01-01
Series:	Heart Views
Subjects:	alirocumab antidrug antibody bococizumab cardiovascular diseases evolocumab familial hypercholesterolemia neurocognitive proprotein convertase subtilisin-kexin type 9 inhibitors
Online Access:	http://www.heartviews.org/article.asp?issn=1995-705X;year=2020;volume=21;issue=2;spage=97;epage=103;aulast=Kaddoura

Similar Items

Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis
by: Yue-Wei Qian, et al.
Published: (2007-07-01)

Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level
by: Olga Afanasieva, et al.
Published: (2020-10-01)

Successful treatment of a patient with refractory nephrotic syndrome with PCSK9 inhibitors: a case report
by: Yuki Awanami, et al.
Published: (2017-07-01)

Clinical Evaluation Of Evolocumab For The Treatment Of Homozygous Familial Hypercholesterolemia In Chinese Patients
by: Huang CC, et al.
Published: (2019-10-01)

PCSK9 Variants in Familial Hypercholesterolemia: A Comprehensive Synopsis
by: Qianyun Guo, et al.
Published: (2020-09-01)

PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE[S]
by: Brandon Ason, et al.
Published: (2014-11-01)

Proprotein convertase subtilisin/Kexin type-9 (PCSK-9) inhibitors induced liver injury - a retrospective analysis
by: Yousuf Zafar, et al.
Published: (2020-01-01)

Effects of Evolocumab on Carotid Intima-Media Thickness and Clinical Parameters in Patients Taking a Statin
by: Keiji Hirai, et al.
Published: (2020-07-01)

Cross-country comparison in the evaluation of evolocumab by health technology assessment agencies in England, Canada, and Australia
by: Swaroop Varghese, et al.
Published: (2019-01-01)

Functional analysis of sites within PCSK9 responsible for hypercholesterolemias⃞
by: Shilpa Pandit, et al.
Published: (2008-06-01)

A new method for measurement of total plasma PCSK9: clinical applications
by: Geneviève Dubuc, et al.
Published: (2010-01-01)

PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunction
by: Hua Sun, et al.
Published: (2018-02-01)

Treatment of atherogenic dyslipidemia: modern principles and new possibilities
by: M. G Bubnova
Published: (2017-06-01)

PCSK9: a convertase that coordinates LDL catabolism
by: Jay D. Horton, et al.
Published: (2009-01-01)

Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells
by: Florent Lalanne, et al.
Published: (2005-06-01)

Proteolytic cleavage of antigen extends the durability of an anti-PCSK9 monoclonal antibody[S]
by: Krista M. Schroeder, et al.
Published: (2015-11-01)

Plasma PCSK9 correlates with apoB-48-containing triglyceride-rich lipoprotein production in men with insulin resistance
by: Jean-Philippe Drouin-Chartier, et al.
Published: (2018-08-01)

Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study
by: Erik Stroes, et al.
Published: (2016-09-01)

The predictive utility of circulating PCSK9 levels on diabetes mellitus
by: Jia Peng, et al.
Published: (2021-02-01)

Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients
by: Bruce A. Warden, PharmD, et al.
Published: (2020-03-01)

PCSK9 Biology and Its Role in Atherothrombosis
by: Cristina Barale, et al.
Published: (2021-05-01)

High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol
by: Greg Welder, et al.
Published: (2010-09-01)

Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice
by: Yi Luo, et al.
Published: (2009-08-01)

Modern strategy of treatment hypercholesterolemia
by: Игорь Владимирович Кузнецов
Published: (2015-03-01)

The association of the PCSK9 rs562556 polymorphism with serum lipids level: a meta-analysis
by: Junlan Chuan, et al.
Published: (2019-04-01)

Janus kinase activation by cytokine oncostatin M decreases PCSK9 expression in liver cells[S]
by: Aiqin Cao, et al.
Published: (2011-03-01)

Editorial: PCSK9: Importance in Physiology and Pathophysiology
by: Rainer Schulz, et al.
Published: (2021-07-01)

Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential
by: Kosmas CE, et al.
Published: (2020-10-01)

Levels of proprotein convertase subtilisin/kexin type 9 in patients with acute myocardial infarction
by: A. D. Gimadeeva, et al.
Published: (2020-03-01)

Cell-based, bioluminescent assay for monitoring the interaction between PCSK9 and the LDL receptor
by: Sarah J. Duellman, et al.
Published: (2017-08-01)

The PCSK9 decade
by: Gilles Lambert, et al.
Published: (2012-12-01)

PCSK9 inhibitors in clinical practice: Novel directions and new experiences
by: Loukianos S. Rallidis, et al.
Published: (2020-07-01)

Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors
by: Øystein L. Holla, et al.
Published: (2011-10-01)

PCSK9 in acute coronary syndrome: analysis of associations with clinical and laboratory characteristics
by: Yu. A. Drenina, et al.
Published: (2020-09-01)

Mutational Spectrum of LDLR and PCSK9 Genes Identified in Iranian Patients With Premature Coronary Artery Disease and Familial Hypercholesterolemia
by: Arman Moradi, et al.
Published: (2021-02-01)

PCSK9 loss-of-function variants and Lp(a) phenotypes among black US adults
by: Matthew T. Mefford, et al.
Published: (2019-11-01)

PCSK9 gene participates in the development of primary dyslipidemias
by: Matías-Pérez D, et al.
Published: (2021-07-01)

The rs508487, rs236911, and rs236918 Genetic Variants of the Proprotein Convertase Subtilisin–Kexin Type 7 (<i>PCSK7</i>) Gene Are Associated with Acute Coronary Syndrome and with Plasma Concentrations of HDL-Cholesterol and Triglycerides
by: Gilberto Vargas-Alarcón, et al.
Published: (2021-06-01)

Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia
by: R. Huijgen, et al.
Published: (2012-05-01)

Circulating PCSK9 levels and 2-hPG are positively correlated in metabolic diseases in a Chinese Han population
by: Wen Guo, et al.
Published: (2018-01-01)

Cannot write session to /tmp/vufind_sessions/sess_cmvqa2j1iv4aegotj4nmtlfceg